Originally published as JCO Early Release 10.1200/JCO.2005.05.4791 on January 29 2007

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carver, B. S. Articles by Sheinfeld, J. Search for Related Content PubMed PubMed Citation Articles by Carver, B. S. Articles by Sheinfeld, J. Related Articles Related Editorial Social Bookmarking                            What's this?

Long-Term Clinical Outcome After Postchemotherapy Retroperitoneal Lymph Node Dissection in Men With Residual Teratoma

Brett S. Carver, Bobby Shayegan, Angel Serio, Robert J. Motzer, George J. Bosl, Joel Sheinfeld

From the Department of Urology and Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

Address reprint requests to Brett S. Carver, MD, Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, 353 E 68th St, New York, NY 10021; e-mail: carverb{at}mskcc.org

Purpose The histologic finding of teratoma occurs in approximately 40% of all postchemotherapy retroperitoneal lymph node dissections (PC-RPLND). We evaluated patients at our institution undergoing initial PC-RPLND for teratoma to determine their clinical outcome.

Patients and Methods We identified 210 patients from 1989 to 2003 with nonseminomatous germ cell tumors (NSGCT) who underwent initial PC-RPLND and were found to have only teratoma in the retroperitoneum. Clinical and pathologic information was obtained from our prospective surgical database, and clinical outcome was reported.

Results Of the 210 patients in our series, 192 (92%) received only induction chemotherapy, and 18 (9%) required additional chemotherapy regimens. PC-RPLND pathology revealed mature teratoma in 178 patients (85%), immature teratoma in 15 patients (7%), and teratoma with malignant transformation in 17 patients (8%). With a median follow-up time for survivors of 37 months, disease recurred in 30 patients. The probability of remaining free of disease recurrence at 5 and 10 years was 83% and 80%, respectively. Of the 30 patients with disease recurrence, 10 (33%) had recurrence with teratoma, five (17%) had recurrence with teratoma with malignant transformation, and 15 (50%) had recurrence with viable germ cell tumor. On multivariable analysis, residual mass size and International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification were predictors of disease recurrence (P < .0005 and = .001, respectively).

Conclusion PC-RPLND remains critical in the management of patients with NSGCT. Patients found to have teratoma at PC-RPLND have a 10-year probability of freedom from recurrence of 80%. The size of the residual mass and IGCCCG risk classification were significant predictors of disease recurrence.

published online ahead of print at www.jco.org on January 29, 2007.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Role of the Urologist in Metastatic Testicular Cancer
  Lawrence H. Einhorn
  JCO 2007 25: 1024-1025 [Full Text]

This article has been cited by other articles:

				B. S. Carver, B. Shayegan, S. Eggener, J. Stasi, R. J. Motzer, G. J. Bosl, and J. Sheinfeld Incidence of Metastatic Nonseminomatous Germ Cell Tumor Outside the Boundaries of a Modified Postchemotherapy Retroperitoneal Lymph Node Dissection J. Clin. Oncol., October 1, 2007; 25(28): 4365 - 4369. [Abstract] [Full Text] [PDF]

				L. H. Einhorn Role of the Urologist in Metastatic Testicular Cancer J. Clin. Oncol., March 20, 2007; 25(9): 1024 - 1025. [Full Text] [PDF]